Summary & Overview
HCPCS J0593: Lanadelumab-flyo Injection, 1 mg
HCPCS Level II code J0593 designates a 1 mg injection of lanadelumab-flyo administered under direct physician supervision. This code matters nationally as lanadelumab is a specialty biologic used for prevention of hereditary angioedema attacks; accurate coding ensures appropriate coverage determinations and billing for physician-supervised administration rather than patient self-administration. Payers commonly involved in coverage decisions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find an overview of the clinical context for lanadelumab-flyo, typical sites of service, and payer relevance for physician-supervised injectable therapy. The publication provides benchmarks and coding guidance context, highlights common payer considerations for billing physician-administered specialty drugs, and summarizes the policy and reimbursement topics readers should watch for when using J0593. Information includes service line implications for physician offices and outpatient clinics and notes where input data is not available. Data not available in the input.
Billing Code Overview
HCPCS Level II code J0593 describes an injection of lanadelumab-flyo, billed per 1 mg. The code is intended for administration of the drug when it is given under the direct supervision of a physician rather than self-administered by the patient.
Service Type
- Drug administration, physician-supervised injectable therapy
Typical Site of Service
- Physician office or outpatient clinic where the injection is administered under direct physician supervision
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent with hereditary angioedema (HAE) receiving in-clinic administration of lanadelumab-flyo. The patient presents to an outpatient specialty infusion clinic, allergy/immunology office, or hospital outpatient department for a scheduled subcutaneous injection when self-administration is not appropriate (for example, the patient lacks training, has dexterity issues, or the payer requires clinician administration). The workflow includes check-in, verification of identity and insurance, review of indication and prior authorization, medication preparation by trained staff, informed consent and assessment of recent HAE attack history, baseline vital signs and allergy review, administration of J0593 (dose documented in mg and lot number), 15–30 minutes post-injection observation for adverse reactions, documentation of injection site, and billing with appropriate modifiers and diagnosis codes. Clinician or qualified healthcare professional supervises the drug administration and documents medical necessity, route, dose, and administration setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | When no modifier applies to the service |
22 |